Earnings Call
Aug 5, 2026
Q2 FY2026
EPS Estimate
2.74
EPS Actual
3.02
Post-Earnings Close
$260.72
Earnings Reaction
+11.4%
Charles River Laboratories posted a cleaner-than-expected second quarter, with organic revenue returning to positive territory for the first time since Q3 2023, a milestone that management was careful to frame as the beginning of a recovery rather than a full inflection. Non-GAAP EPS of $3.02 came in well above the prior outlook of at least 30% sequential growth, driven by better-than-expected top-line performance and a favorable nonoperating contribution from the company's deferred compensation plan. The organic revenue print of +0.1% versus guidance of a low single-digit decline was the headline surprise, and management responded by raising full-year organic revenue guidance by 150 basis points to flat-to-up 1% and lifting EPS guidance to $11.15, $11.45, representing 8%, 11% year-over-year growth.
Report generated on Aug 5, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full CRL analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.